Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Infection-related hyperammonemia in patients with urea cycle disorders is an important cause of morbidity and mortality. The relationship between immune system cells and the metabolic pathways used by these cells and inborn errors of metabolism is still under investigation. Current studies are generally based on experiments in mice. The investigators' goal is to study specific T cell subsets to understand the effects of the urea cycle on T cells.
The investigators collected blood samples from participants with lysinuric protein intolerance and urea cycle disorders for basic immunophenotyping, lymphocyte proliferation in response to phytohemagglutinin and CDmix, and cytokine analysis involving Th1, Th2, and Th17 and compared them with age-matched healthy controls. They also examined amino acid profiles in sera and supernatants before and after stimulation with PMA-ionomycin.
The investigators aim to compare cellular immune response of T cell phenotype and proliferative functions in addition to lymphocyte subset analysis between urea cycle disorders and healthy controls.
Complete blood counts, immunoglobuline levels, lymptocyte subset analysis and Thelper cells will be analyzed. Additionally, T helper cells will be measured regarding their cytokine profile as Th1, Th2 and Th17. T cell proliferation response and aminoacid profiles in supernatants before and after stimulation will be measured.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with urea cycle disorder | Patients with inborn errors of metabolism resulting from defects in one of the enzymes or transporter molecules involved in the hepatic removal of ammonia from the bloodstream | ||
| Patients with lysinuric protein intolerance | Patients with disorder caused by the body's inability to digest and use certain protein building blocks (amino acids), namely lysine, arginine, and ornithine | ||
| Healthy control | Children without any comorbidity and chronic diseases. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of Th1, Th2 and Th17 cells | Th1, Th2 and Th17 cells will be measured following stimulation in cell culture | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of T cell proliferative capacity | T cells' proliferation will be measured following stimulation in cell culture | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of amino acid profile changes before and after stimulation | Serum Aminoacids from periphery, in cell culture supernatants before and after stimulation will be measured | baseline |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients with a diagnosis of urea cycle disorders and lysinuric protein intolerance
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ayca Kiykim | Istanbul University - Cerrahpasa | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istanbul University-Cerrahpasa | Istanbul | 34098 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D056806 | Urea Cycle Disorders, Inborn |
| C562687 | Lysinuric Protein Intolerance |
| ID | Term |
|---|---|
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009422 | Nervous System Diseases |
| D000592 | Amino Acid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |